1513.HK

Livzon Pharmaceutical Group Inc. [1513.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

1513.HK Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

1513.HK has less than 1 year of cash runway

Top 10 Correlated ETFs

1513.HK

Top 10 Correlated Stocks

1513.HK

In the News

1513.HK Financial details

Company Rating

Buy

Market Cap

32.19B

Income

1.95B

Revenue

12.43B

Book val./share

Cash/share

Dividend

1.74

Dividend %

7.67%

Employees

8.93K

Optionable

Shortable

Yes

Earnings

24 Apr 2024

P/E

10.64

Forward P/E

PEG

-6.58

P/S

2.28

P/B

1.56

P/C

P/FCF

13.31

Quick Ratio

2.01

Current Ratio

2.33

Debt / Equity

0.29

LT Debt / Equity

0.11

EPS (TTM)

1.71

EPS next Y

EPS next Q

EPS this Y

2.94%

EPS next Y

EPS next 5Y

EPS last 5Y

8.6%

Revenue last 5Y

5.78%

Revenue Q/Q

-6.4%

EPS Q/Q

SMA20

-10.71%

SMA50

4.17%

SMA100

4.17%

Inst Own

Inst Trans

ROA

ROE

15%

ROC

0.14%

Gross Margin

63%

Oper. Margin

19%

Profit Margin

16%

Payout

78%

Shs Outstand

Shs Float

Target Price

52W Range

21.5-30.15

52W High

-15.5%

52W Low

+20.71%

RSI

Rel Volume

1.42

Avg Volume

599.62K

Volume

851.9K

Perf Week

0.6%

Perf Month

-11.52%

Perf Quarter

8.33%

Perf Half Y

3.47%

Beta

0.246

Volatility

0.23%, 1.26%

Prev Close

-2.12%

Price

25.35

Change

-0.78%

1513.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	10.04	11.24	12.91	13.52	13.36
Net income per share	1.39	1.83	1.9	2.04	2.1
Operating cash flow per share	1.89	2.31	2.04	2.97	3.49
Free cash flow per share	1.46	1.62	0.63	1.96	2.61
Cash per share	9.49	10.66	9.98	11.26	12.26
Book value per share	11.95	12.93	13.92	14.86	15.09
Tangible book value per share	12.62	13.94	14.31	15	14.97
Share holders equity per share	11.95	12.93	13.92	14.86	15.09
Interest debt per share	1.46	2.09	2.97	3.98	4.56
Market cap	20.24B	23.67B	21.74B	21.65B	20.4B
Enterprise value	12.75B	15.65B	15.28B	14.86B	13.22B
P/E ratio	15.54	13.8	12.24	11.34	10.44
Price to sales ratio	2.16	2.25	1.8	1.71	1.64
POCF ratio	11.45	10.96	11.43	7.81	6.28
PFCF ratio	14.78	15.64	36.64	11.81	8.4
P/B Ratio	1.81	1.96	1.67	1.56	1.45
PTB ratio	1.81	1.96	1.67	1.56	1.45
EV to sales	1.36	1.49	1.27	1.18	1.06
Enterprise value over EBITDA	5.86	5.26	5.35	4.53	3.6
EV to operating cash flow	7.21	7.24	8.03	5.36	4.07
EV to free cash flow	9.31	10.34	25.76	8.11	5.44
Earnings yield	0.06	0.07	0.08	0.09	0.1
Free cash flow yield	0.07	0.06	0.03	0.08	0.12
Debt to equity	0.12	0.16	0.21	0.26	0.29
Debt to assets	0.08	0.09	0.12	0.15	0.17
Net debt to EBITDA	-3.44	-2.7	-2.26	-2.07	-1.96
Current ratio	2.43	2.4	2.12	2.3	2.14
Interest coverage	238.44	98.78	26.99	24.1	23.66
Income quality	1.21	1.01	0.97	1.42	1.71
Dividend Yield	0.04	0.05	0.06	0.06	0.08
Payout ratio	0.67	0.64	0.71	0.68	0.81
Sales general and administrative to revenue	0.03	0.02	0.02	0.05	0.05
Research and developement to revenue	0.08	0.08	0.09	0.11	0.11
Intangibles to total assets	0.03	0.03	0.04	0.04	0.03
Capex to operating cash flow	-0.23	-0.3	-0.69	-0.34	-0.25
Capex to revenue	-0.04	-0.06	-0.11	-0.07	-0.07
Capex to depreciation	-1.03	-1.64	-2.94	-1.44	-0.98
Stock based compensation to revenue	0	0	0	0	0
Graham number	19.36	23.09	24.39	26.15	26.71
ROIC	0.12	0.15	0.13	0.11	0.11
Return on tangible assets	0.07	0.09	0.08	0.08	0.08
Graham Net	6.19	6.52	5.15	5.17	5.34
Working capital	7.58B	8.54B	7.75B	9.59B	9.18B
Tangible asset value	11.79B	13.05B	13.37B	14.01B	13.93B
Net current asset value	7.17B	7.68B	6.61B	7.06B	6.99B
Invested capital	0.12	0.16	0.21	0.26	0.29
Average receivables	2.67B	2.91B	3.37B	3.95B	4.02B
Average payables	1.31B	1.44B	1.72B	1.84B	1.76B
Average inventory	1.14B	1.33B	1.58B	1.85B	2.05B
Days sales outstanding	105.15	107.85	109.61	123.86	110.01
Days payables outstanding	135.93	161.43	155.96	152.34	135.56
Days of inventory on hand	125.79	147.82	142.74	167.34	168.43
Receivables turnover	3.47	3.38	3.33	2.95	3.32
Payables turnover	2.69	2.26	2.34	2.4	2.69
Inventory turnover	2.9	2.47	2.56	2.18	2.17
ROE	0.12	0.14	0.14	0.14	0.14
Capex per share	-0.43	-0.69	-1.4	-1.01	-0.88

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.36	3.65	3.52	3.19	0
Net income per share	0.43	0.62	0.59	0.5	0
Operating cash flow per share	0.43	0.62	1	1.06	0
Free cash flow per share	0.27	0.47	0.72	0.89	0
Cash per share	11.26	11.73	11.73	11.21	0
Book value per share	14.86	15.3	14.4	14.66	0
Tangible book value per share	15	15.6	14.37	14.67	0
Share holders equity per share	14.86	15.3	14.4	14.66	0
Interest debt per share	3.9	4.36	4.6	4.34	0
Market cap	21.65B	22.61B	23.2B	22.24B	0
Enterprise value	14.86B	15.8B	16.62B	15.89B	-7.18B
P/E ratio	13.44	9.72	10.49	11.9	0
Price to sales ratio	6.89	6.63	7.08	7.5	0
POCF ratio	53.77	38.86	25.01	22.57	0
PFCF ratio	85.61	51.93	34.37	26.81	0
P/B Ratio	1.56	1.58	1.73	1.63	0
PTB ratio	1.56	1.58	1.73	1.63	0
EV to sales	4.73	4.63	5.07	5.36	-2.59
Enterprise value over EBITDA	30.88	19.86	22.24	23.67	-11.59
EV to operating cash flow	36.9	27.14	17.92	16.13	-6.93
EV to free cash flow	58.75	36.27	24.62	19.16	-9.32
Earnings yield	0.02	0.03	0.02	0.02	0
Free cash flow yield	0.01	0.02	0.03	0.04	0
Debt to equity	0.26	0.28	0.32	0.29	0.29
Debt to assets	0.15	0.16	0.17	0.16	0.17
Net debt to EBITDA	-14.12	-8.57	-8.81	-9.45	-11.59
Current ratio	2.3	2.43	2.18	2.33	2.14
Interest coverage	18.05	32.61	26.49	21.51	15.61
Income quality	1	1	1.68	2.11	0
Dividend Yield	0	0	0.03	0.04	0
Payout ratio	0.06	0.05	1.1	1.93	0.14
Sales general and administrative to revenue	0.03	0.04	-0.02	0.13	0.06
Research and developement to revenue	0.14	0.09	0.09	0.13	0.13
Intangibles to total assets	0.04	0.03	0.03	0.03	0.03
Capex to operating cash flow	-0.37	-0.25	-0.27	-0.16	-0.26
Capex to revenue	-0.05	-0.04	-0.08	-0.05	-0.1
Capex to depreciation	-0.23	0	-0.53	0.33	0
Stock based compensation to revenue	0.02	0	0.01	-0.01	0
Graham number	12.01	14.64	13.87	12.87	0
ROIC	0.02	0.03	0.03	0.03	0.02
Return on tangible assets	0.02	0.02	0.02	0.02	0.01
Graham Net	5.17	5.64	4.32	4.7	0
Working capital	9.59B	10.51B	9.69B	9.68B	9.18B
Tangible asset value	14.01B	14.57B	13.38B	13.65B	13.93B
Net current asset value	7.06B	7.66B	6.45B	6.65B	6.99B
Invested capital	0.26	0.28	0.32	0.29	0.29
Average receivables	4.16B	4.41B	4.56B	4.43B	4.01B
Average payables	1.8B	1.89B	1.92B	1.86B	1.73B
Average inventory	1.93B	2.14B	2.25B	2.2B	2.1B
Days sales outstanding	122.78	119.56	125.92	129.66	121.5
Days payables outstanding	140.97	137.19	151.26	150.04	151.87
Days of inventory on hand	154.85	159.81	177.96	178.5	188.71
Receivables turnover	0.73	0.75	0.71	0.69	0.74
Payables turnover	0.64	0.66	0.59	0.6	0.59
Inventory turnover	0.58	0.56	0.51	0.5	0.48
ROE	0.03	0.04	0.04	0.03	0.03
Capex per share	-0.16	-0.16	-0.27	-0.17	0

1513.HK Dividend History

1513.HK Frequently Asked Questions

What is Livzon Pharmaceutical Group Inc. stock symbol ?

Livzon Pharmaceutical Group Inc. is a CN stock and trading under the symbol 1513.HK

What is Livzon Pharmaceutical Group Inc. stock quote today ?

Livzon Pharmaceutical Group Inc. stock price is $25.35 today.

Is Livzon Pharmaceutical Group Inc. stock public?

Yes, Livzon Pharmaceutical Group Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 599.62K
Market Capitalization 32.19B
Employee 8.93K
CEO Mr. Yanggang Tang
Headquarters Zhuhai,CN
IPO Date 2014-01-16
Website https://www.livzon.com.cn

Livzon Pharmaceutical Group Inc. engages in the research, development, production, and sale of pharmaceutical products, and active pharmaceutical ingredients and intermediates in the People's Republic of China. The company offers Ilaprazole enteric coated tablets for the treatment of duodenal ulcers and reflux esophagitis; Laprazole sodium for injection to treat peptic ulcer hemorrhage; Leuprorelin Acetate Microspheres for injection; Urofollitropin for injection to treat anovulation and sufferers; Perospirone Hydrochloride for the treatment of schizophrenia; Anti-viral Granules to treat upper respiratory tract infection and influenza; and Shenqi Fuzheng Injection for the treatment of weakness and tiredness, lassitude, spontaneous sweating, and vertigo, as well as for the patients of lung and stomach cancer. It also offers diagnostic reagents, such as diagnostic kit for IgM/IgG antibody to coronavirus; nucleic acid test kit for human immunodeficiency virus type 1; antinuclear antibody test kits; interferon-gamma release assays test kits; and rapid test for mycoplasma pneumoniae IgM antibody. In addition, the company provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, and antibiotics. It also exports its products. The company was founded in 1985 and is headquartered in Zhuhai, China.